▶ 調査レポート

世界のアヘン拮抗薬市場(~2028年):0.4mg/ml、1mg/ml、2mg/ml

• 英文タイトル:Global Opiate Antagonist Market Insights, Forecast to 2028

Global Opiate Antagonist Market Insights, Forecast to 2028「世界のアヘン拮抗薬市場(~2028年):0.4mg/ml、1mg/ml、2mg/ml」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-19290
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、117ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品&医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、アヘン拮抗薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
アヘン拮抗薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
アヘン拮抗薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
アヘン拮抗薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までのアヘン拮抗薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のアヘン拮抗薬の売上および2028年までの予測に焦点を当てています。

アヘン拮抗薬のグローバル主要企業には、Pfizer、Sun Pharmaceutical Industries、Teva Pharmaceuticals、Cardinal Health、Baxter Pharmaceutical、Adapt Pharmaceuticals、Dr. Reddy's Laboratories、GIV Repack、Intl Medication Systems、Kaleo Pharma、Mylan Institutional、Perrigo Pharmaceuticals、AuroMedics Pharma、Somerset Pharma、Akorn、Alkermesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

アヘン拮抗薬市場は、タイプとアプリケーションによって区分されます。世界のアヘン拮抗薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
0.4mg/ml、1mg/ml、2mg/ml

【アプリケーション別セグメント】
病院、クリニック、薬局、家庭、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- アヘン拮抗薬製品概要
- タイプ別市場(0.4mg/ml、1mg/ml、2mg/ml)
- アプリケーション別市場(病院、クリニック、薬局、家庭、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のアヘン拮抗薬販売量予測2017-2028
- 世界のアヘン拮抗薬売上予測2017-2028
- アヘン拮抗薬の地域別販売量
- アヘン拮抗薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別アヘン拮抗薬販売量
- 主要メーカー別アヘン拮抗薬売上
- 主要メーカー別アヘン拮抗薬価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(0.4mg/ml、1mg/ml、2mg/ml)
- アヘン拮抗薬のタイプ別販売量
- アヘン拮抗薬のタイプ別売上
- アヘン拮抗薬のタイプ別価格
・アプリケーション別市場規模(病院、クリニック、薬局、家庭、その他)
- アヘン拮抗薬のアプリケーション別販売量
- アヘン拮抗薬のアプリケーション別売上
- アヘン拮抗薬のアプリケーション別価格
・北米市場
- 北米のアヘン拮抗薬市場規模(タイプ別、アプリケーション別)
- 主要国別のアヘン拮抗薬市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのアヘン拮抗薬市場規模(タイプ別、アプリケーション別)
- 主要国別のアヘン拮抗薬市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のアヘン拮抗薬市場規模(タイプ別、アプリケーション別)
- 主要国別のアヘン拮抗薬市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のアヘン拮抗薬市場規模(タイプ別、アプリケーション別)
- 主要国別のアヘン拮抗薬市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのアヘン拮抗薬市場規模(タイプ別、アプリケーション別)
- 主要国別のアヘン拮抗薬市場規模(トルコ、サウジアラビア)
・企業情報
Pfizer、Sun Pharmaceutical Industries、Teva Pharmaceuticals、Cardinal Health、Baxter Pharmaceutical、Adapt Pharmaceuticals、Dr. Reddy's Laboratories、GIV Repack、Intl Medication Systems、Kaleo Pharma、Mylan Institutional、Perrigo Pharmaceuticals、AuroMedics Pharma、Somerset Pharma、Akorn、Alkermes
・産業チェーン及び販売チャネル分析
- アヘン拮抗薬の産業チェーン分析
- アヘン拮抗薬の原材料
- アヘン拮抗薬の生産プロセス
- アヘン拮抗薬の販売及びマーケティング
- アヘン拮抗薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- アヘン拮抗薬の産業動向
- アヘン拮抗薬のマーケットドライバー
- アヘン拮抗薬の課題
- アヘン拮抗薬の阻害要因
・主な調査結果

Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Opiate Antagonist estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Opiate Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Opiate Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Opiate Antagonist is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Opiate Antagonist include Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Cardinal Health, Baxter Pharmaceutical, Adapt Pharmaceuticals, Dr. Reddy’s Laboratories, GIV Repack and Intl Medication Systems, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Opiate Antagonist companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Opiate Antagonist market. Further, it explains the major drivers and regional dynamics of the global Opiate Antagonist market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer
Sun Pharmaceutical Industries
Teva Pharmaceuticals
Cardinal Health
Baxter Pharmaceutical
Adapt Pharmaceuticals
Dr. Reddy’s Laboratories
GIV Repack
Intl Medication Systems
Kaleo Pharma
Mylan Institutional
Perrigo Pharmaceuticals
AuroMedics Pharma
Somerset Pharma
Akorn
Alkermes
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Opiate Antagonist Segment by Type
0.4 mg/ml
1 mg/ml
2 mg/ml
Opiate Antagonist Segment by Application
Hospital
Clinics
Pharmacy
Home
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Opiate Antagonist market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Opiate Antagonist market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Opiate Antagonist, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Opiate Antagonist, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Opiate Antagonist revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Opiate Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Opiate Antagonist revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Cardinal Health, Baxter Pharmaceutical, Adapt Pharmaceuticals, Dr. Reddy’s Laboratories, GIV Repack and Intl Medication Systems, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Opiate Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Opiate Antagonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opiate Antagonist revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Opiate Antagonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 0.4 mg/ml
1.2.3 1 mg/ml
1.2.4 2 mg/ml
1.3 Market by Application
1.3.1 Global Opiate Antagonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Pharmacy
1.3.5 Home
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Opiate Antagonist Market Perspective (2017-2028)
2.2 Opiate Antagonist Growth Trends by Region
2.2.1 Opiate Antagonist Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Opiate Antagonist Historic Market Size by Region (2017-2022)
2.2.3 Opiate Antagonist Forecasted Market Size by Region (2023-2028)
2.3 Opiate Antagonist Market Dynamics
2.3.1 Opiate Antagonist Industry Trends
2.3.2 Opiate Antagonist Market Drivers
2.3.3 Opiate Antagonist Market Challenges
2.3.4 Opiate Antagonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Opiate Antagonist Players by Revenue
3.1.1 Global Top Opiate Antagonist Players by Revenue (2017-2022)
3.1.2 Global Opiate Antagonist Revenue Market Share by Players (2017-2022)
3.2 Global Opiate Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Opiate Antagonist Revenue
3.4 Global Opiate Antagonist Market Concentration Ratio
3.4.1 Global Opiate Antagonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Opiate Antagonist Revenue in 2021
3.5 Opiate Antagonist Key Players Head office and Area Served
3.6 Key Players Opiate Antagonist Product Solution and Service
3.7 Date of Enter into Opiate Antagonist Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Opiate Antagonist Breakdown Data by Type
4.1 Global Opiate Antagonist Historic Market Size by Type (2017-2022)
4.2 Global Opiate Antagonist Forecasted Market Size by Type (2023-2028)
5 Opiate Antagonist Breakdown Data by Application
5.1 Global Opiate Antagonist Historic Market Size by Application (2017-2022)
5.2 Global Opiate Antagonist Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Opiate Antagonist Market Size (2017-2028)
6.2 North America Opiate Antagonist Market Size by Type
6.2.1 North America Opiate Antagonist Market Size by Type (2017-2022)
6.2.2 North America Opiate Antagonist Market Size by Type (2023-2028)
6.2.3 North America Opiate Antagonist Market Share by Type (2017-2028)
6.3 North America Opiate Antagonist Market Size by Application
6.3.1 North America Opiate Antagonist Market Size by Application (2017-2022)
6.3.2 North America Opiate Antagonist Market Size by Application (2023-2028)
6.3.3 North America Opiate Antagonist Market Share by Application (2017-2028)
6.4 North America Opiate Antagonist Market Size by Country
6.4.1 North America Opiate Antagonist Market Size by Country (2017-2022)
6.4.2 North America Opiate Antagonist Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Opiate Antagonist Market Size (2017-2028)
7.2 Europe Opiate Antagonist Market Size by Type
7.2.1 Europe Opiate Antagonist Market Size by Type (2017-2022)
7.2.2 Europe Opiate Antagonist Market Size by Type (2023-2028)
7.2.3 Europe Opiate Antagonist Market Share by Type (2017-2028)
7.3 Europe Opiate Antagonist Market Size by Application
7.3.1 Europe Opiate Antagonist Market Size by Application (2017-2022)
7.3.2 Europe Opiate Antagonist Market Size by Application (2023-2028)
7.3.3 Europe Opiate Antagonist Market Share by Application (2017-2028)
7.4 Europe Opiate Antagonist Market Size by Country
7.4.1 Europe Opiate Antagonist Market Size by Country (2017-2022)
7.4.2 Europe Opiate Antagonist Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Opiate Antagonist Market Size (2017-2028)
8.2 Asia-Pacific Opiate Antagonist Market Size by Type
8.2.1 Asia-Pacific Opiate Antagonist Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Opiate Antagonist Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Opiate Antagonist Market Share by Type (2017-2028)
8.3 Asia-Pacific Opiate Antagonist Market Size by Application
8.3.1 Asia-Pacific Opiate Antagonist Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Opiate Antagonist Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Opiate Antagonist Market Share by Application (2017-2028)
8.4 Asia-Pacific Opiate Antagonist Market Size by Region
8.4.1 Asia-Pacific Opiate Antagonist Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Opiate Antagonist Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Opiate Antagonist Market Size (2017-2028)
9.2 Latin America Opiate Antagonist Market Size by Type
9.2.1 Latin America Opiate Antagonist Market Size by Type (2017-2022)
9.2.2 Latin America Opiate Antagonist Market Size by Type (2023-2028)
9.2.3 Latin America Opiate Antagonist Market Share by Type (2017-2028)
9.3 Latin America Opiate Antagonist Market Size by Application
9.3.1 Latin America Opiate Antagonist Market Size by Application (2017-2022)
9.3.2 Latin America Opiate Antagonist Market Size by Application (2023-2028)
9.3.3 Latin America Opiate Antagonist Market Share by Application (2017-2028)
9.4 Latin America Opiate Antagonist Market Size by Country
9.4.1 Latin America Opiate Antagonist Market Size by Country (2017-2022)
9.4.2 Latin America Opiate Antagonist Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Opiate Antagonist Market Size (2017-2028)
10.2 Middle East & Africa Opiate Antagonist Market Size by Type
10.2.1 Middle East & Africa Opiate Antagonist Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Opiate Antagonist Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Opiate Antagonist Market Share by Type (2017-2028)
10.3 Middle East & Africa Opiate Antagonist Market Size by Application
10.3.1 Middle East & Africa Opiate Antagonist Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Opiate Antagonist Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Opiate Antagonist Market Share by Application (2017-2028)
10.4 Middle East & Africa Opiate Antagonist Market Size by Country
10.4.1 Middle East & Africa Opiate Antagonist Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Opiate Antagonist Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Opiate Antagonist Introduction
11.1.4 Pfizer Revenue in Opiate Antagonist Business (2017-2022)
11.1.5 Pfizer Recent Developments
11.2 Sun Pharmaceutical Industries
11.2.1 Sun Pharmaceutical Industries Company Details
11.2.2 Sun Pharmaceutical Industries Business Overview
11.2.3 Sun Pharmaceutical Industries Opiate Antagonist Introduction
11.2.4 Sun Pharmaceutical Industries Revenue in Opiate Antagonist Business (2017-2022)
11.2.5 Sun Pharmaceutical Industries Recent Developments
11.3 Teva Pharmaceuticals
11.3.1 Teva Pharmaceuticals Company Details
11.3.2 Teva Pharmaceuticals Business Overview
11.3.3 Teva Pharmaceuticals Opiate Antagonist Introduction
11.3.4 Teva Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.3.5 Teva Pharmaceuticals Recent Developments
11.4 Cardinal Health
11.4.1 Cardinal Health Company Details
11.4.2 Cardinal Health Business Overview
11.4.3 Cardinal Health Opiate Antagonist Introduction
11.4.4 Cardinal Health Revenue in Opiate Antagonist Business (2017-2022)
11.4.5 Cardinal Health Recent Developments
11.5 Baxter Pharmaceutical
11.5.1 Baxter Pharmaceutical Company Details
11.5.2 Baxter Pharmaceutical Business Overview
11.5.3 Baxter Pharmaceutical Opiate Antagonist Introduction
11.5.4 Baxter Pharmaceutical Revenue in Opiate Antagonist Business (2017-2022)
11.5.5 Baxter Pharmaceutical Recent Developments
11.6 Adapt Pharmaceuticals
11.6.1 Adapt Pharmaceuticals Company Details
11.6.2 Adapt Pharmaceuticals Business Overview
11.6.3 Adapt Pharmaceuticals Opiate Antagonist Introduction
11.6.4 Adapt Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.6.5 Adapt Pharmaceuticals Recent Developments
11.7 Dr. Reddy’s Laboratories
11.7.1 Dr. Reddy’s Laboratories Company Details
11.7.2 Dr. Reddy’s Laboratories Business Overview
11.7.3 Dr. Reddy’s Laboratories Opiate Antagonist Introduction
11.7.4 Dr. Reddy’s Laboratories Revenue in Opiate Antagonist Business (2017-2022)
11.7.5 Dr. Reddy’s Laboratories Recent Developments
11.8 GIV Repack
11.8.1 GIV Repack Company Details
11.8.2 GIV Repack Business Overview
11.8.3 GIV Repack Opiate Antagonist Introduction
11.8.4 GIV Repack Revenue in Opiate Antagonist Business (2017-2022)
11.8.5 GIV Repack Recent Developments
11.9 Intl Medication Systems
11.9.1 Intl Medication Systems Company Details
11.9.2 Intl Medication Systems Business Overview
11.9.3 Intl Medication Systems Opiate Antagonist Introduction
11.9.4 Intl Medication Systems Revenue in Opiate Antagonist Business (2017-2022)
11.9.5 Intl Medication Systems Recent Developments
11.10 Kaleo Pharma
11.10.1 Kaleo Pharma Company Details
11.10.2 Kaleo Pharma Business Overview
11.10.3 Kaleo Pharma Opiate Antagonist Introduction
11.10.4 Kaleo Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.10.5 Kaleo Pharma Recent Developments
11.11 Mylan Institutional
11.11.1 Mylan Institutional Company Details
11.11.2 Mylan Institutional Business Overview
11.11.3 Mylan Institutional Opiate Antagonist Introduction
11.11.4 Mylan Institutional Revenue in Opiate Antagonist Business (2017-2022)
11.11.5 Mylan Institutional Recent Developments
11.12 Perrigo Pharmaceuticals
11.12.1 Perrigo Pharmaceuticals Company Details
11.12.2 Perrigo Pharmaceuticals Business Overview
11.12.3 Perrigo Pharmaceuticals Opiate Antagonist Introduction
11.12.4 Perrigo Pharmaceuticals Revenue in Opiate Antagonist Business (2017-2022)
11.12.5 Perrigo Pharmaceuticals Recent Developments
11.13 AuroMedics Pharma
11.13.1 AuroMedics Pharma Company Details
11.13.2 AuroMedics Pharma Business Overview
11.13.3 AuroMedics Pharma Opiate Antagonist Introduction
11.13.4 AuroMedics Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.13.5 AuroMedics Pharma Recent Developments
11.14 Somerset Pharma
11.14.1 Somerset Pharma Company Details
11.14.2 Somerset Pharma Business Overview
11.14.3 Somerset Pharma Opiate Antagonist Introduction
11.14.4 Somerset Pharma Revenue in Opiate Antagonist Business (2017-2022)
11.14.5 Somerset Pharma Recent Developments
11.15 Akorn
11.15.1 Akorn Company Details
11.15.2 Akorn Business Overview
11.15.3 Akorn Opiate Antagonist Introduction
11.15.4 Akorn Revenue in Opiate Antagonist Business (2017-2022)
11.15.5 Akorn Recent Developments
11.16 Alkermes
11.16.1 Alkermes Company Details
11.16.2 Alkermes Business Overview
11.16.3 Alkermes Opiate Antagonist Introduction
11.16.4 Alkermes Revenue in Opiate Antagonist Business (2017-2022)
11.16.5 Alkermes Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer